Top

Published in:

01-09-2013 | Original Paper

Role of KAI1/CD82 polymorphisms in colon cancer risk in Han Chinese population

Authors: Zhen-Bin Ma, Kun Li, Jian Wang, Guang-Hong Guo

Published in: Medical Oncology | Issue 3/2013

Abstract

The aim of this study is to investigate the associations between KAI1/CD82 gene polymorphisms and colorectal cancer (CRC)-risk predisposition. We undertook a case–control study to analyze two KAI1/CD82 polymorphisms (exon 3 −29166 C>T and exon 9 −52840 C>A) in an Han Chinese population, by extraction of genomic DNA from the peripheral blood of 356 patients with CRC and 378 control participants, and performed KAI1/CD82 genotyping using DNA sequencing. The obtained results indicated that overall, no statistically significant association was observed in exon 9 (−52840 C>A). Nevertheless, exon 3 (−29166 C>T) genotype was at increased risk of CRC (P = 0.006; odds ratio = 1.299, CI 95 % 1.058–1.549). Furthermore, −29166 T allele CRCs were more significantly common in patients with tumor size of >4 cm than C allele CRC and in cases of poor differentiation and advanced pathological stage. These findings led us to conclude that polymorphism in exon 3 (−29166 C>T) was observed to be associated with susceptibility of CRC. However, exon 9 (−52840 C>A) polymorphism showed no correlation to CRC susceptibility. Nevertheless, further investigation with a larger sample size is needed to support our results.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.PubMedCrossRef

Zhu QC, Jin ZM. Efficacy and side effects of combination therapy of oxaliplatin and S-1 for colorectal cancer. Zhonghua Zhong Liu Za Zhi. 2011;33(5):388–90.PubMed

Booth RA. Minimally invasive biomarkers for detection and staging of colorectal cancer. Cancer Lett. 2007;249(1):87–96. doi:10.1016/j.canlet.2006.12.021.PubMedCrossRef

Moreaux J, Catala M. Carcinoma of the colon: long-term survival and prognosis after surgical treatment in a series of 798 patients. World J Surg. 1987;11(6):804–9.PubMedCrossRef

Burt RW. Strategies for colon cancer screening with considerations of cost and access to care. J Natl Compr Canc Netw. 2010;8(1):2–5.PubMed

Ye Y, Madison B, Wu X, Rustgi AK. A LIN28B polymorphism predicts for colon cancer survival. Cancer Biol Ther. 2012;13(14):1390–5. doi:10.4161/cbt.22336.PubMedCrossRef

Zhang L, Zhang G, Wang P, Gong J, Cao Y, Tang L. Association of vascular endothelial growth factor −2578C/A gene polymorphism in Chinese patients with colon cancer. Genet Test Mol Biomarkers. 2011;15(3):117–21. doi:10.1089/gtmb.2010.0166.PubMedCrossRef

Slattery ML, Herrick J, Curtin K, Samowitz W, Wolff RK, Caan BJ, et al. Increased risk of colon cancer associated with a genetic polymorphism of SMAD7. Cancer Res. 2010;70(4):1479–85. doi:10.1158/0008-5472.CAN-08-1792.PubMedCrossRef

Rubinstein E, Le Naour F, Billard M, Prenant M, Boucheix C. CD9 antigen is an accessory subunit of the VLA integrin complexes. Eur J Immunol. 1994;24(12):3005–13. doi:10.1002/eji.1830241213.PubMedCrossRef

10.

Mannion BA, Berditchevski F, Kraeft SK, Chen LB, Hemler ME. Transmembrane-4 superfamily proteins CD81 (TAPA-1), CD82, CD63, and CD53 specifically associated with integrin alpha 4 beta 1 (CD49d/CD29). J Immunol. 1996;157(5):2039–47.PubMed

11.

Hemler ME, Mannion BA, Berditchevski F. Association of TM4SF proteins with integrins: relevance to cancer. Biochim Biophys Acta. 1996;1287(2–3):67–71.PubMed

12.

Wright MD, Tomlinson MG. The ins and outs of the transmembrane 4 superfamily. Immunol Today. 1994;15(12):588–94. doi:10.1016/0167-5699(94)90222-4.PubMedCrossRef

13.

Hashida H, Takabayashi A, Tokuhara T, Hattori N, Taki T, Hasegawa H, et al. Clinical significance of transmembrane 4 superfamily in colon cancer. Br J Cancer. 2003;89(1):158–67. doi:10.1038/sj.bjc.6601015.PubMedCrossRef

14.

Dong JT, Suzuki H, Pin SS, Bova GS, Schalken JA, Isaacs WB, et al. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res. 1996;56(19):4387–90.PubMed

15.

Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, et al. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science. 1995;268(5212):884–6.PubMedCrossRef

16.

Friess H, Guo XZ, Berberat P, Graber HU, Zimmermann A, Korc M, et al. Reduced KAI1 expression in pancreatic cancer is associated with lymph node and distant metastases. Int J Cancer. 1998;79(4):349–55. doi:10.1002/(SICI)1097-0215(19980821)79:4<349:AID-IJC7>3.0.CO;2-V.PubMedCrossRef

17.

Yu Y, Yang JL, Markovic B, Jackson P, Yardley G, Barrett J, et al. Loss of KAI1 messenger RNA expression in both high-grade and invasive human bladder cancers. Clin Cancer Res. 1997;3(7):1045–9.PubMed

18.

Yang X, Welch DR, Phillips KK, Weissman BE, Wei LL. KAI1, a putative marker for metastatic potential in human breast cancer. Cancer Lett. 1997;119(2):149–55. doi:S0304-3835(97)00273-5.PubMedCrossRef

19.

Higashiyama M, Kodama K, Yokouchi H, Takami K, Adachi M, Taki T, et al. KAI1/CD82 expression in nonsmall cell lung carcinoma is a novel, favorable prognostic factor: an immunohistochemical analysis. Cancer. 1998;83(3):466–74. doi:10.1002/(SICI)1097-0142(19980801)83:3<466:AID-CNCR15>3.0.CO;2-U.PubMedCrossRef

20.

Hinoda Y, Adachi Y, Takaoka A, Mitsuuchi H, Satoh Y, Itoh F, et al. Decreased expression of the metastasis suppressor gene KAI1 in gastric cancer. Cancer Lett. 1998;129(2):229–34. doi:S0304-3835(98)00112-8.PubMedCrossRef

21.

Uchida S, Shimada Y, Watanabe G, Li ZG, Hong T, Miyake M, et al. Motility-related protein (MRP-1/CD9) and KAI1/CD82 expression inversely correlate with lymph node metastasis in oesophageal squamous cell carcinoma. Br J Cancer. 1999;79(7–8):1168–73. doi:10.1038/sj.bjc.6690186.PubMedCrossRef

22.

Dong JT, Isaacs WB, Barrett JC, Isaacs JT. Genomic organization of the human KAI1 metastasis-suppressor gene. Genomics. 1997;41(1):25–32. doi:10.1006/geno.1997.4618.PubMedCrossRef

23.

Nazir M, Kayani MR, Malik FA, Masood N, Kayani MA. Lack of germ line changes in KISS1 and KAI1 genes in sporadic head and neck cancer patients of Pakistani origin. Asian Pac J Cancer Prev. 2011;12(10):2767–71.PubMed

24.

Boland CR. Molecular genetics of hereditary nonpolyposis colorectal cancer. Ann N Y Acad Sci. 2000;910:50–9; discussion 9–61.

25.

Edge SB. American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.

26.

Miyake M, Hakomori SI. A specific cell surface glycoconjugate controlling cell motility: evidence by functional monoclonal antibodies that inhibit cell motility and tumor cell metastasis. Biochemistry. 1991;30(13):3328–34.PubMedCrossRef

27.

Hashida H, Takabayashi A, Adachi M, Imai T, Kondo K, Kohno N, et al. The novel monoclonal antibody MH8-4 inhibiting cell motility recognizes integrin alpha 3: inverse of its expression withmetastases in colon cancer. Int J Oncol. 2001;18(1):89–95.PubMed

28.

Hashida H, Takabayashi A, Kanai M, Adachi M, Kondo K, Kohno N, et al. Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology. 2002;122(2):376–86. doi:S0016508502084482.PubMedCrossRef

29.

Gu J, Tamura M, Pankov R, Danen EH, Takino T, Matsumoto K, et al. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J Cell Biol. 1999;146(2):389–403.PubMedCrossRef

30.

Kolesnikova TV, Stipp CS, Rao RM, Lane WS, Luscinskas FW, Hemler ME. EWI-2 modulates lymphocyte integrin alpha4beta1 functions. Blood. 2004;103(8):3013–9. doi:10.1182/blood-2003-07-2201.PubMedCrossRef

31.

Miyazaki T, Kato H, Shitara Y, Yoshikawa M, Tajima K, Masuda N, et al. Mutation and expression of the metastasis suppressor gene KAI1 in esophageal squamous cell carcinoma. Cancer. 2000;89(5):955–62. doi:10.1002/1097-0142(20000901)89:5<955:AID-CNCR3>3.0.CO;2-Z.PubMedCrossRef

32.

Kawana Y, Komiya A, Ueda T, Nihei N, Kuramochi H, Suzuki H, et al. Location of KAI1 on the short arm of human chromosome 11 and frequency of allelic loss in advanced human prostate cancer. Prostate. 1997;32(3):205–13. doi:10.1002/(SICI)1097-0045(19970801)32:3<205:AID-PROS7>3.0.CO;2-J.PubMedCrossRef

33.

Uzawa K, Ono K, Suzuki H, Tanaka C, Yakushiji T, Yamamoto N, et al. High prevalence of decreased expression of KAI1 metastasis suppressor in human oral carcinogenesis. Clin Cancer Res. 2002;8(3):828–35.PubMed

Title: Role of KAI1/CD82 polymorphisms in colon cancer risk in Han Chinese population
Authors: Zhen-Bin Ma
Kun Li
Jian Wang
Guang-Hong Guo
Publication date: 01-09-2013
Publisher: Springer US
Published in: Medical Oncology / Issue 3/2013
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-013-0668-7

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Role of KAI1/CD82 polymorphisms in colon cancer risk in Han Chinese population

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2013

Androgen receptor in human prostate cancer-associated fibroblasts promotes prostate cancer epithelial cell growth and invasion

Association between single genetic polymorphisms of MDR1 gene and gastric cancer susceptibility in Chinese

UGT1A1*6/*28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients

Prognostic value of the Glasgow Prognostic Score in metastatic colorectal cancer in the era of anti-EGFR therapies

Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy

Identification of a 5-gene signature for clinical and prognostic prediction in gastric cancer patients upon microarray data

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

UGT1A16/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients